BioCurex, Inc.(fka BOCX)

[Sleeper Cell]

"... demonstrates the results obtained with the assay format used in several automated instruments including the Abbott Architect(tm). 68 breast, gastric and other types of cancers were compared to 52 normal patients and the AUC(1) scoring obtained was 0.954 (a perfect discrimination between cancer and normal samples has a score of 1.0). Similar results were independently obtained in our Licensee's facility for prostate cancer samples."

Do you guys realize what this means? It means that the assay works on "several automated instruments", not just the Architect. This opens the door for more licensing deals, and is very attractive because the format has already been converted the chemiluminescent assay format and would only have to wait on FDA approval. Time to market is very near for these prospective pharmas that may want to license this technology! I hope Wall Street gives this an appropriate response in the pps come tomorrow!